Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HYP-6589 alone in advanced solid tumors and with osimertinib in target-driven advanced non-small cell lung cancer
CTR20244228Phase 2Active
- Sponsor
- Huiyu Haiyue
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HY-0006, osimertinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), sponsored by Huiyu Haiyue. Started Dec 2024; status: active.
02
Drugs
HY-0006osimertinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244228.